Sleep quality is critical for positive mental health, and sleep disorders can worsen mental health conditions. Similarly, mental health problems can result in poor sleep. Neurologist and sleep expert Dr. Anne Marie Morse explains the bidirectional relationship between sleep and mental health, and how she addresses both problems with her patients. In the words of Dr. Morse: “The duration, quality and timing of sleep can actually be predictive to the development of adverse mental health outcomes.”
Advertisement
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
What is the relationship between blood urea nitrogen-to-serum albumin ratio and mortality in ICU patients with T2D and CKD?
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
The phase 3 global, multi-center trial included 492 patients with stage IV NSCLC.
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
eGenesis has received financing to help advance an engineered kidney, EGEN-2784, to a first-in-human study for transplant.
How does early vs delayed treatment with long-acting ESAs affect renal and cardiovascular outcomes in patients with NDD-CKD?
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
DocWire Content Partners
Powered by DocWire News
The Latest From GI Oncology Now
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
Researchers utilized a deep learning model to combine data and develop personalized treatment response predictions.
Researchers specifically used data from the SEER-22 and SEER-17 registries.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
The Latest From Heme Today
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
Lactate dehydrogenase level was pinpointed as a significant predictor of thromboembolism and mortality.
A study has assessed cryogenically preserved ovarian tissue samples from women with SCD for any effects from hydroxyurea.
A multicenter, double-blind, randomized study found no clinically significant difference in efficacy or safety.